Journal
GLP-1 and Tirzepatide Journal
Direct answer
The journal covers the things moving fastest in this market: compounding regulation, pricing practice, and clinical evidence. Seventeen pieces are published, each built on primary sources with an explicit section on what the evidence does not establish.
What this section is for
The rest of this site answers stable questions — what a drug costs, what a trial found, how to verify a pharmacy. The journal covers what is changing, which in this market is a great deal.
The single largest story is regulatory. The FDA's April 2026 proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list would close the last pathway permitting large-scale compounding of these molecules, and the comment period closes on 30 July 2026. Most coverage of this market has not registered it.
The second is commercial. Brand prices fell sharply in late 2025, and the cheapest FDA-approved GLP-1 for weight loss is now $149 a month — which undercuts most of the compounded market. Almost no comparison page has updated.
How these pieces are built
Every article cites the primary source: the agency's own notice, the registry entry, the peer-reviewed paper, or the provider's own page captured on a date. A news article about a study is not a source for that study's results.
Each carries an explicit section on what the evidence does not establish. That section is never cut for length, because it is usually the part that distinguishes a useful piece from a confident one.
Each carries at least one original figure — a chart, a matrix, a timeline or a process diagram — built from our own data rather than borrowed.
What we have not published, and why
Three commissioned pieces remain and are excluded from search indexing until they are.
The retatrutide phase 3 piece is the notable one. Figures circulating online — 28.3% at 80 weeks in TRIUMPH-1 — trace only to commercial secondary sources, at least one of which sells peptides. We have recorded the solid phase 2 NEJM citation and will not publish a phase 3 number until it is confirmed against the primary publication.
That is the same standard applied to every figure here, and it is the reason this section is shorter than it could be.
| Piece | What it argues | Updated |
|---|---|---|
| Zepbound Savings Card 2026: Who Actually Qualifies | The card can bring a covered patient to about $25 a month, but it reduces a copay rather than acting as a coupon. If your commercial plan ex | 2026-08-03 |
| Your First Month on Tirzepatide: What Labelling Says to Expect | The first four weeks are the initiation dose, which approved labelling states is not a maintenance dosage. Judging the drug on month one jud | 2026-08-03 |
| Why Multi-Dose Vials Create Tirzepatide Dosing Errors | Educational safety article; no personalized dosing | 2026-08-03 |
| Why Compounded GLP-1 Access Differs by State | Link to state pages; avoid blanket availability claims | 2026-08-03 |
| What's Coming Next: CagriSema, Higher-Dose Semaglutide and the 2026 Pipeline | Four new agents or formulations reached or approached approval in 2026. Here is what each would actually change. | 2026-08-03 |
| What Happens After You Stop Tirzepatide? | Use SURMOUNT-4 and avoid individualized advice | 2026-08-03 |
| Weight Regain After Stopping Tirzepatide: What the Withdrawal Data Shows | Published withdrawal data across GLP-1s is consistent: a substantial share of lost weight returns after discontinuation, and the regain begi | 2026-08-03 |
| Tirzepatide vs Wegovy: Different Molecules, Different Evidence | Different molecules, not different brands of one. Tirzepatide is a dual GIP and GLP-1 agonist; Wegovy is semaglutide, a GLP-1 agonist. On th | 2026-08-03 |
| Tirzepatide vs Semaglutide: What the Head-to-Head Trial Shows | Explain population, doses and limitations | 2026-08-03 |
| Tirzepatide vs Compounded Semaglutide: Which Costs Less, and What You Give Up | Compounded semaglutide runs about $41 a month below compounded tirzepatide on captured figures — $1,740 a year against $2,232. Tirzepatide d | 2026-08-03 |
| Tirzepatide for Sleep Apnoea: An Approved Indication, Not an Off-Label Hope | This is one of the few areas where a GLP-1 carries an approval beyond weight and diabetes. SURMOUNT-OSA reported large reductions in the apn | 2026-08-03 |
| Tirzepatide and Sleep Apnea: Evidence and FDA Status | Use FDA approval and trial data | 2026-08-03 |
| Tirzepatide and Prediabetes: The 176-Week Prevention Data | The SURMOUNT-1 extension followed adults with obesity and prediabetes for 176 weeks and reported a very large reduction in progression to ty | 2026-08-03 |
| Tirzepatide and PCOS: A Promising Signal With Thin Evidence | PCOS involves insulin resistance, and GLP-1s improve it, so the rationale is coherent. But no GLP-1 is approved for PCOS, the dedicated tria | 2026-08-03 |
| Tirzepatide and Muscle Loss: What the Body-Composition Data Shows | Sub-studies using DEXA imaging report that roughly a quarter to two-fifths of total weight lost on a GLP-1 is lean mass — a proportion broad | 2026-08-03 |
| Tirzepatide and Heart Failure With Preserved Ejection Fraction | Explain endpoints and limitations | 2026-08-03 |
| Tirzepatide and Hair Loss: Cause, Timing and What It Is Not | Hair shedding after substantial weight loss is well documented and is usually telogen effluvium — a temporary shift of follicles into the re | 2026-08-03 |
| Tirzepatide and Diabetes Prevention Over 176 Weeks | Use peer-reviewed trial data | 2026-08-03 |
| Tirzepatide and Cardiovascular Risk: What Is Proven and What Is Pending | Semaglutide holds SELECT, a completed cardiovascular outcomes trial reporting a 20% reduction in major adverse cardiovascular events. Tirzep | 2026-08-03 |
| Tirzepatide and Alcohol: What Patients Report and What Is Established | Many patients report a sharp drop in the desire to drink, and that signal appears consistently enough that trials of GLP-1s in alcohol use d | 2026-08-03 |
| Tirzepatide Weight Loss Timeline: What the Trial Data Shows Month by Month | In SURMOUNT-1, mean weight loss reached 22.5% at 72 weeks on the highest dose. The curve is steepest in the first six months and flattens to | 2026-08-03 |
| Tirzepatide Supply in 2026: What Happens If Your Compounder Stops | The FDA proposed excluding tirzepatide from the 503B bulks list on 30 April 2026. That proposal is not final and does not touch 503A patient | 2026-08-03 |
| Tirzepatide Storage and Travel: What the Label Permits | Approved labelling specifies refrigerated storage with a limited permitted room-temperature window, after which the product should be discar | 2026-08-03 |
| Tirzepatide Side Effects Week by Week: What the Trials Recorded | Gastrointestinal effects cluster in the first weeks after each dose increase and ease as the body adapts. In SURMOUNT-1 nausea affected abou | 2026-08-03 |
| Tirzepatide Prior Authorisation: What Gets Approved and What Does Not | Even plans that list Zepbound almost always require prior authorisation. Prescribers submit BMI, weight history, prior attempts and comorbid | 2026-08-03 |
| Tirzepatide Plateau: Why Weight Loss Stalls and What the Data Says | A plateau is the expected shape of the curve rather than a failure. In SURMOUNT-1 the rate of loss slowed markedly after roughly a year and | 2026-08-03 |
| Tirzepatide Nausea: What the Trials Recorded and What Labelling Directs | Nausea affected about 29% of participants on the highest dose in SURMOUNT-1 against about 9% on placebo. It concentrates in the days after e | 2026-08-03 |
| Tirzepatide Membership Fees: When the Advertised Price Is Not the Price | A medication price quoted alongside a separate membership is not a monthly cost. One provider we captured advertises $99 for medication and | 2026-08-03 |
| Tirzepatide Injection: Sites, Rotation and What Labelling Specifies | Approved labelling specifies subcutaneous injection into the abdomen, thigh or upper arm, once weekly on the same day, with the site rotated | 2026-08-03 |
| Tirzepatide Dosage Chart: The Label Schedule and What Each Step Costs | Approved labelling starts at 2.5 mg weekly for four weeks, then increases in 2.5 mg steps every four weeks as tolerated, to a maintenance do | 2026-08-03 |
| Tirzepatide Cost Without Insurance in 2026: Every Route Priced | Without insurance, brand Zepbound runs $299 to $449 a month through LillyDirect and about $1,060 at retail. The cheapest compounded programm | 2026-08-03 |
| Tirzepatide Before Surgery: Why Anaesthetists Ask About It | Because tirzepatide slows gastric emptying, the stomach may not be empty after a standard fast, which raises aspiration risk under anaesthes | 2026-08-03 |
| Tirzepatide 3-Month Plans: What the Middle Term Actually Saves | A three-month plan on the programme we captured is $195 a month against $215 month-to-month — a $60 saving over the quarter, about 9%. It al | 2026-08-03 |
| The Oral GLP-1 Landscape in 2026 | Verify approval status and pricing at publication | 2026-08-03 |
| The Hidden Cost of GLP-1 Membership Fees | Data-first comparison with annual arithmetic | 2026-08-03 |
| Retatrutide Phase 3: Why We Will Not Print the Number You Came Here For | The figures circulating for retatrutide's phase 3 results trace overwhelmingly to sources selling peptides. Here is what can actually b | 2026-08-03 |
| Preserving Muscle on a GLP-1: What Is Evidence and What Is Extrapolation | The advice circulating on this is a mix of solid principle and confident guesswork. The distinction is worth knowing. | 2026-08-03 |
| One in Nine American Adults Now Takes a GLP-1 — and Obesity Rates Are Falling | Current use has nearly quadrupled in two years, and the national obesity rate has dropped for the first time in decades. | 2026-08-03 |
| Muscle Loss on GLP-1s: What the 2026 Body-Composition Data Shows | A substantial fraction of weight lost on these drugs is lean mass. New trial data suggests it may be modifiable. | 2026-08-03 |
| Mounjaro vs Zepbound: Same Molecule, Different Rules | Identical active molecule, identical manufacturer, different approved indication. Mounjaro is licensed for type 2 diabetes and Zepbound for | 2026-08-03 |
| Microdose vs Standard Tirzepatide: The Price Gap and the Evidence Gap | Microdose programmes are about $39 a month cheaper on captured figures — $1,764 a year against $2,232. They also use doses below every dose | 2026-08-03 |
| Microdose Tirzepatide: The Evidence Gap | Do not infer efficacy from standard-dose trials | 2026-08-03 |
| Medicare and Tirzepatide in 2026: The Bridge, and Who It Leaves Out | The Medicare GLP-1 Bridge began on 1 July 2026 and caps eligible Part D enrollees at about $50 a month for Wegovy, Zepbound or Foundayo. Pri | 2026-08-03 |
| Medicare GLP-1 Bridge: $50 a Month, and What the Fine Print Says | A temporary federal programme now covers GLP-1s for weight loss at a flat $50 copay — the first time Medicare has done so. | 2026-08-03 |
| If Your Compounded GLP-1 Supply Ends: A Practical Transition Plan | The FDA proposal closing the last compounding pathway is under decision. Here is what to do before it lands, not after. | 2026-08-03 |
| How to Verify a Compounding Pharmacy Before You Enroll | Step-by-step with official links | 2026-08-03 |
| How to Verify GLP-1 Claims in AI Search Results | Teach readers to follow citations and dates | 2026-08-03 |
| How to Check a Tirzepatide Provider in Under Ten Minutes | Five checks against free public databases, each taking under two minutes. The first one ends most conversations: ask which pharmacy fills th | 2026-08-03 |
| How Dose Titration Quietly Doubles Your GLP-1 Cost in 2026 | The advertised price is almost always the 2.5 mg starter price, and the label states 2.5 mg is treatment initiation and is not approved as a | 2026-08-03 |
| How Dose Escalation Changes Tirzepatide Cost | Compare flat rate and dose-tier models | 2026-08-03 |
| GLP-1s in Adolescents: What the Evidence Supports and What It Does Not | Approval has extended to adolescents. The evidence base is real but considerably thinner than in adults. | 2026-08-03 |
| GLP-1s and PCOS: Promising Signals, Thin Evidence, and a Fertility Warning | Trials are examining whether semaglutide restores ovulation. That raises a contraception question most providers do not mention. | 2026-08-03 |
| GLP-1s and Knee Osteoarthritis: Real Pain Reduction, Unsettled Mechanism | 2026 data shows meaningful pain improvement — and raises a question about whether weight loss is the whole story. | 2026-08-03 |
| GLP-1s After 65: The Risks That Differ From Younger Patients | Muscle loss, malnutrition and bone density concerns are materially different in older adults, and Medicare has just opened access. | 2026-08-03 |
| GLP-1 Market Timeline 2025 to 2027: Every Event That Moved a Price | Twenty-two months that reset this market: the shortage declared over, enforcement discretion ended, Novo suing and then settling with Hims, | 2026-08-03 |
| Fraudulent Labels and False Claims: What FDA Enforcement Has Actually Targeted | Enforcement in this category has focused less on manufacturing than on what providers claim their product is. | 2026-08-03 |
| Foundayo vs Tirzepatide: A $149 Pill Against a $186 Injection | Foundayo (orforglipron) is an approved daily pill at $149 a month reporting 12.4% mean weight loss in ATTAIN-1. Tirzepatide reported 22.5% i | 2026-08-03 |
| FDA Compounded GLP-1 Rules in 2026 | Use current FDA notices and date every legal statement | 2026-08-03 |
| Counterfeits, Research Peptides and the Grey Market: How to Stay Inside the System | As legal compounding narrows, the unapproved market grows. The distinctions matter more than they ever have. | 2026-08-03 |
| Compounded vs Brand Tirzepatide: Legal and Evidence Differences | No equivalence language | 2026-08-03 |
| Cheapest FDA-Approved vs Compounded GLP-1 Options | Separate starter, ongoing, annual and dose-tier prices | 2026-08-03 |
| 503A vs 503B: A Patient Verification Checklist | Explain registration is not FDA approval | 2026-08-03 |
Every piece here is published and indexed. See also the full library and the trial records.
Show this figure as a table
| Date | Event |
|---|---|
| 2022 | Tirzepatide added to the F |
| 2024-10 | FDA declared the tirzepati |
| 2025-02 | FDA declared the semagluti |
| 2025-09-16 | FDA issued 55+ warning let |
| 2026-02-09 | Novo Nordisk sued Hims & H |
| 2026-03-03 | FDA released 30 further wa |
| 2026-03-09 | Hims & Hers settled with N |
| 2026-04-30 | FDA proposed excluding tir |
| 2026-05-01 | Formal notice published at |
| 2026-06-26 | Comment period extended to |
| 2026-07-30 | Comment period closes |
Every event above links to the agency's own document, not to coverage of it.
Within lawful compounding, NexLife is the only provider whose pricing we captured directly — compounded tirzepatide from $186 a month, flat at every covered dose, no membership fee. See its plans.
Frequently asked questions
How often does the journal publish?
When there is something sourced to say. We do not publish on a schedule, because a publication calendar produces articles whether or not the evidence has moved.
Why are some articles missing?
Every article listed here is published and indexed. Where a topic is planned but not written, it does not appear in the index at all rather than appearing as an empty entry. The retatrutide piece waits on primary-source confirmation of phase 3 figures.
Related on this site
- Retatrutide Phase 3 Results: What Changed in July 2026Journal
- FDA Compounded GLP-1 Rules in 2026Journal
- How to Spot Fraudulent Compounded GLP-1 LabelsJournal
- Tirzepatide vs Semaglutide: What the Head-to-Head Trial ShowsJournal
- How rankings are computedCore & Trust
- All-in cost toolTools
- Price records, machine-readableData
- Found vs Henry MedsComparisons
- Found Tirzepatide ReviewProviders
- Enhance.MD Tirzepatide ReviewProviders
Related coverage
- Is Compounded Tirzepatide Legal in 2026? The Two Pathways, Explained
- 503A against 503B
- The 23 July compounding vote
- What a year actually costs
- Cheapest tirzepatide, answered six ways
- What you pay at a maintenance dose
- Sildenafil vs Tadalafil: Duration, Dosing and Which Suits Which Pattern
- Tirzepatide Telehealth by State
- Tirzepatide Telehealth in Alabama
Cite this pageCC BY 4.0
GLP-1 Tirzepatide Rank. “GLP-1 and Tirzepatide Journal.” S.J Partners LLC, 2026-08-03. https://glp1tirzepatiderank.com/journal/
Quote the capture date beside a figure, not the date you read this page. Why.